References
Abbott RD, Ross GW, Petrovitch H, Tanner CM, Davis DG, Masaki KH, et al. 2007. Bowel movement frequency in late‑life and incidental Lewy bodies. Mov Disord 22(11):1581–1586.
Abbott RD, Ross GW, White LR, Tanner CM, Masaki KH, Nelson JS, et al. 2005. Excessive daytime sleepiness and sub sequent development of Parkinson disease. Neurology 65(9):1442–1446.
Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. 2005. Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology 65(9):1436–1441.
Annanmaki T, Muuronen A, Murros K. 2007. Low plasma uric acid level in Parkinson’s disease. Mov Disord 22(8):1133–1137.
Ascherio A, Weisskopf MG, O’Reilly EJ, McCullough ML, Calle EE, Rodriguez C, et al. 2004. Coffee consumption, gender, and Parkinson’s disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. Am J Epidemiol 160(10):977–984.
Ascherio A, Zhang SM, Hernán MA, Kawachi I, Colditz GA, Speizer FE, et al. 2001. Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann Neurol 50(1):56–63.
Becker C, Jick SS, Meier CR. 2008. Use of statins and the risk of Parkinson’s disease: a retrospective case-control study in the UK. Drug Saf 31(5):399–407.
Bower JH, Maraganore DM, McDonnell SK, Rocca WA. 1999. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990. Neurology 52:1214–1220.
Bower JH, Maraganore DM, Peterson BJ, McDonnell SK, Ahlskog JE, Rocca WA. 2003. Head trauma preceding PD: a case-control study. Neurology 60(10):1610–1615.
Braak H, Ghebremedhim E, Rub U, Bratzke H, Del Tredici K. 2004. Stages in the development of Parkinson’s disease—related pathology. Cell Tissue Res 318(1):121–134.
Burn DJ, Rowan EN, Allan LM, Molloy S, O’Brien JT, McKeith IG. 2006. Motor subtype and cognitive decline in Parkinson’s disease, Parkinson’s disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 77(5):585–589.
Chade AR, Kasten M, Tanner CM. 2006. Nongenetic causes of Parkinson’s disease. J Neural Transml 70(suppl):147–151.
Chen H, Zhang S, Hernan M, Willett W, Ascherio A. 2002. Diet and Parkinson’s disease: a potential role of dairy products in men. Ann Neurol 52:793– 801.
Currie LJ, Harrison MB, Trugman JM, Bennett JP, Wooten GF. 2004. Postmenopausal estrogen use affects risk for Parkinson disease. Arch Neurol 61(6):886–888.
Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM. 1996. Observations on serum uric acid levels and the risk of idiopathic Parkinson’s disease. Am J Epidemiol 144(5):480–484.
de Lau LM, Bornebroek M, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM. 2005. Dietary fatty acids and the risk of Parkinson disease: the Rotterdam study. Neurology 64(12):2040–2045.
de Pedro-Cuesta J. 1991. Parkinson’s disease occurrence in Europe. Acta Neurol Scand 84(4):357–365.
de Rijk MC, Breteler MM, Graveland GA, Ott A, Grobbee DE, van der Meché FG, et al. 1995. Prevalence of Parkinson’s disease in the elderly: the Rotterdam Study. Neurology 45(12):2143–2146.
de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S. 1997. Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s disease. J Neurol Neurosurg Psychiatry 62(1):10–15.
Dick FD. 2006. Parkinson’s disease and pesticide exposures. Br Med Bull 79–80:219–231.
Dick FD, De Palma G, Ahmadi A, Scott NW, Prescott GJ, Bennett J, et al. 2007. Environmental risk factors for Parkinson’s disease and parkinsonism: the Geoparkinson study. Occup Environ Med 64(10):666–672.
Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. 2007. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68(5):384–386.
Drechsel DA, Patel M. 2008. Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson’s disease. Free Radic Biol Med 1;44(11):1873–1886.
Elbaz A. 2008. LRRK2: bridging the gap between sporadic and hereditary Parkinson’s disease. Lancet Neurol 7(7):562–564.
Etminan M, Gill SS, Samii A. 2005. Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson’s disease: a meta-analysis. Lancet Neurol 4(6):362–365.
Frigerio R, Elbaz A, Sanft KR, Peterson BJ, Bower JH, Ahlskog JE, et al. 2005. Education and occupations preceding Parkinson disease: a population-based case-control study. Neurology 65(10):1575–1583.
Gao X, Chen H, Choi HK, Curhan G, Schwarzschild MA, Ascherio A. 2008. Diet, urate, and Parkinson’s disease risk in men. Am J Epidemiol 167(7):831–838.
Gao X, Chen H, Fung TT, Logroscino G, Schwarzschild MA, Hu FB, et al. 2007. Prospective study of dietary pattern and risk of Parkinson disease. Am J Clin Nutr 86(5):1486–1494.
Goldman SM, Tanner CM, Oakes D, Bhudhikanok GS, Gupta A, Langston JW. 2006. Head injury and Parkinson’s disease risk in twins. Ann Neurol 60(1):65–72.
Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. 1998. The risk of Parkinson’s disease with exposure to pesticides, farming, well water, and rural living. Neurology 50:1346–1350.
Hancock DB, Martin ER, Mayhew GM, Stajich JM, Jewett R, Stacy MA, et al. 2008. Pesticide exposure and risk of Parkinson’s disease: a family-based case-control study. BMC Neurol 8:6.
Hernan MA, Takkouche B, Caamanolsoma F, Gestel-Otero J. 2002. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol 52:276–284.
Hertzman C, Wiens M, Snow B, Kelly S, Calne D. 1994. A case-control study of Parkinson’s disease in a horticultural region of British Columbia. Mov Disord 9:69–75.
Hu G, Antikainen R, Jousilahti P, Kivipelto M, Tuomilehto J. 2008. Total cholesterol and the risk of Parkinson disease. Neurology 70(21):1972–1979.
Hu G, Jousilahti P, Nissinen A, Antikainen R, Kivipelto M, Tuomilehto J. 2006. Body mass index and the risk of Parkinson disease. Neurology 67(11):1955–1959.
Kamel F, Tanner C, Umbach D, Hoppin J, Alavanja M, Blair A, et al. 2007. Pesticide exposure and self-reported Parkinson’s disease in the agricultural health study. Am J Epidemiol 165(4):364–374.
Kuopio AM, Marttila RJ, Helenius H, Rinne UK. 1999. Environmental risk factors in Parkinson’s disease. Mov Disord 14(6):928–939.
Langston JW. 2006. The Parkinson’s complex: parkinsonism is just the tip of the iceberg. Ann Neurol 59(4):591–596.
Langston JW, Ballard P, Tetrud JW, Irwin I. 1983. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219(4587):979–980.
Lee SJ. 2003. Alpha-synuclein aggregation: a link between mitochondrial defects and Parkinson’s disease? Antioxid Redox Signal 5(3):337–348.
Logroscino G, Sesso HD, Paffenbarger RS Jr, Lee IM. 2007. Body mass index and risk of Parkinson’s disease: a prospective cohort study. Am J Epidemiol 166(10):1186–1190.
Marras C, Tanner CM. 2002. The epidemiology of Parkinson’s disease. In: Movement Disorders Neurologic Principles and Practice (Watts RL, Koller WC, eds). New York:McGraw-Hill, 177–196.
Marsh GM, Gula MJ. 2006. Employment as a welder and Parkinson disease among heavy equipment manufacturing workers. J Occup Environ Med 48(10):1031–1046.
Mayeux R, Marder K, Cote LJ, Denaro J, Hemenegildo N, Mejia H, et al. 1995. The frequency of idiopathic Parkinson’s disease by age, ethnic group, and sex in northern Manhattan, 1988–1993. Am J Epidemiol 142(8):820–827.
Mergler D, Huel G, Iregren A, Belanger S, Baldwin M, Tardif R, et al. 1994. Nervous system dysfunction among workers with long-term exposure to manganese. Environ Res 64:151–180.
Park M, Ross GW, Petrovitch H, White LR, Masaki KH, Nelson JS, et al. 2005. Consumption of milk and calcium in midlife and the future risk of Parkinson disease. Neurology 64(6):1047–1051.
Pfeiffer RF. 1998. Gastrointestinal dysfunction in Parkinson’s disease. Clin Neurosci 5(2):136–146.
Popat RA, Van Den Eeden SK, Tanner CM, McGuire V, Bernstein AL, Bloch DA, et al. 2005. Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology 65(3):383–390.
Powers KM, Kay DM, Factor SA, Zabetian CP, Higgins DS, Samii A, et al. 2008a. Combined effects of smoking, coffee, and NSAIDs on Parkinson’s disease risk. Mov Disord 23(1):88–95.
Powers KM, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD, Checkoway H. 2008b. Dietary fats, cholesterol and iron as risk factors for Parkinson’s disease. Parkinsonism Relat Disord; doi:10.1016/j.parkreldis.2008.03.002 [Online 18 April 2008].
Prince MM, Hein MJ, Ruder AM, Waters MA, Laber PA, Whelan EA. 2006. Update: cohort mortality study of workers highly exposed to polychlorinated biphenyls (PCBs) during the manufacture of electrical capacitors, 1940–1998. Environ Health 22;5:13.
Priyadarshi A, Khuder SA, Schaub EA, Priyadarshi SS. 2001. Environmental risk factors and Parkinson’s disease: a metaanalysis. Environ Res 86(2):122–127.
Purisai MG, McCormack AL, Langston WJ, Johnston LC, Di Monte DA. 2005. Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiol Dis 20(3):898–906.
Ritz B, Ascherio A, Checkoway H, Marder KS, Nelson LM, Rocca WA, et al. 2007. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol 64(7):990–997.
Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, et al. 2000. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283(20):2674–2679.
Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K, et al. 2008. Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol 63(2):167–173.
Santamaria AB, Cushing CA, Antonini JM, Finley BL, Mowat FS. 2007. State-of-the-science review: does manganese exposure during welding pose a neurological risk? J Toxicol Environ Health B Crit Rev 10(6):417–465.
Simon KC, Chen H, Schwarzschild M, Ascherio A. 2007. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 69(17):1688–1695.
Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. 2003. Alpha-synuclein locus triplication causes Parkinson’s disease. Science 302(5646):841.
Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. 1998. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 95(11):6469–6473.
Steenland K, Hein MJ, Cassinelli RT 2nd, Prince MM, Nilsen NB, Whelan EA, et al. 2006. Polychlorinated biphenyls and neurodegenerative disease mortality in an occupational cohort. Epidemiology 17(1):8–13.
Stern MB, Doty RL, Dotti M, Corcoran P, Crawford D, McKeown DA. 1994. Olfactory function in Parkinson’s disease subtypes. Neurology 44(2):266–268.
Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, et al. 1999. Parkinson disease in twins: an etiologic study. JAMA 281(4):341–346.
Thacker EL, Chen H, Patel AV, McCullough ML, Calle EE, Thun MJ. 2008. Recreational physical activity and risk of Parkinson’s disease. Mov Disord 23(1):69–74.
Thiruchelvam M, Richfield E, Baggs R, Tank A, Cory-Slechta D. 2000. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson’s disease. J Neurosci 20(24):9207–9214.
Tuchsen F, Jensen AA. 2000. Agricultural work and the risk of Parkinson’s disease in Denmark, 1981–1993. Scand J Work Environ Health 26:359–362.
Uversky V. 2004. Neurotoxicant-induced animal models of Parkinson’s disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res 318(1):225–241.
Uversky V, Li J, Fink A. 2001. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson’s disease. FEBS Lett 500(3):105–108.
Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, et al. 2003. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 157:1015–1022.
Vila M, Vukosavic S, Jackson-Lewis V, Neystat M, Jakowec M, Przedborski S. 2000. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem 74(2):721–729.
Wahner AD, Bronstein JM, Bordelon YM, Ritz B. 2007. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 69(19):1836–1842.
Wahner AD, Bronstein JM, Bordelon YM, Ritz B. 2008. Statin use and the risk of Parkinson disease. Neurology 70(16 pt 2):1418–1422.
Warner T, Schapira A. 2003. Genetic and environmental factors in the cause of Parkinson’s disease. Ann Neurol 53(suppl 3):S16–S25.
Weisskopf M, O’Reilly E, Chen H, Schwarzschild M, Ascherio A. 2007. Plasma urate and risk of Parkinson’s disease. Am J Epidemiol 166(5):561–567.
Wirdefeldt K, Gatz M, Schalling M, Pedersen NL. 2004. No evidence for heritability of Parkinson disease in Swedish twins. Neurology 63(2):305–311.
Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. 2004. Are men at greater risk for Parkinson’s disease than women? J Neurol Neurosurg Psychiatry 75(4):637–639.
Zhang SM, Hernán MA, Chen H, Spiegelman D, Willett WC, Ascherio A. 2002. Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology 59(8):1161–1169.
Zhang ZX, Anderson DW, Huang JB, Li H, Hong X, Wei J. 2003. Prevalence of Parkinson’s disease and related disorders in the elderly population of greater Beijing, China Mov Disord 18(7):764–772.
Zhang ZX, Román GC. 1993. Worldwide occurrence of Parkinson’s disease: an updated review. Neuroepidemiology 12(4):195–208.
Last Updated: December 17, 2008